BYSI stock icon



About: BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.

Employees: 36

Funds holding %
of 6,656 funds
Analysts bullish %
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

24,207% more call options, than puts

Call options by funds: $324K | Put options by funds: $1.33K

9% more capital invested

Capital invested by funds: $4.52M [Q3] → $4.91M (+$388K) [Q4]

0.46% less ownership

Funds ownership: 14.52% [Q3] → 14.05% (-0.46%) [Q4]

23% less funds holding

Funds holding: 26 [Q3] → 20 (-6) [Q4]

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Research analyst outlook

We haven’t received any recent analyst ratings for BYSI.

Financial journalist opinion

Based on 4 articles about BYSI published over the past 30 days